查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197134

血液學市場增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Hematology Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內（2022 年至 2027 年），血液學市場預計將以 5.2% 的複合年增長率增長。

COVID-19 的爆發使全球範圍內對 COVID-19 評估的血液學市場關注，許多醫院使用血細胞計數器等設備對 COVID-19 患者進行檢測和監測。預計將產生重大影響在血液學市場上。 根據 2020 年國際實驗室血液學雜誌發表的一篇研究論文，臨床血液學實驗室應測量感染 SARS-CoV-2 病毒的患者中常見的淋巴細胞減少症、中性粒細胞減少症、白細胞減少症、血小板減少症。它在提供一些重要的作用有用的預後標誌物，如減少。 美國血液學會 2021 年發表的一份報告發現，與沒有 SCD 的黑人相比，患有 COVID-19 和鐮狀細胞病 (SCD) 的人住院、患肺炎和疼痛的風險更高。事實證明，有到 由於 SCD 患者發生其他感染的風險很高，因此了解他們的健康狀況非常重要，這對市場有重大影響。 因此，血液學檢測對感染 COVID-19 的患者的重要性日益增加，將激增各種終端用戶對血液學產品和試劑的需求，從而顯著影響大流行時代研究市場的增長。

血液學市場的增長歸因於血液學和其他疾病發病率的增加、血液學技術的快速進步以及高通量血液學分析儀的出現。 慢性血液病患病率上升預計將推動對血細胞計數器的需求，因此是推動市場的關鍵因素之一。 凝血分析儀可準確檢測血友病等多種血液疾病的凝血終點。 一個人可能會患上各種類型的血液病和血癌。 常見的慢性血液疾病包括貧血、出血性疾病（如血友病和血栓）以及血癌（如白血病、淋巴瘤和骨髓瘤）。 根據美國疾病控制和預防中心 2022 年 5 月的更新，鐮狀細胞病 (SCD) 影響了大約 100,000 名美國人。 它發生在 365 名黑人或非裔美國人出生中的 1 名。 早診斷、早治療是挽救血細胞疾病患者生命的最佳途徑。

此外，主要參與者的技術進步和產品發布正在推動市場的增長。 例如，2022 年 6 月，Thermo Fisher Scientific 宣布了新的 EliA RNA Pol III 和 EliA Rib-P 血液檢測，以幫助診斷系統性硬化症和系統性紅斑狼瘡 (SLE)，這是一種自動結締組織。我們進一步擴展了我們的綜合菜單疾病測試。 根據 2021 年 2 月發表的文章“使用 HemoScreen POC 血液學分析儀的農村研究”，開展了一項農村地區縱向研究 (RURAL) 潛在風險。 本研究將在移動護理單元實驗室部署技術先進的 HemoScreen 血細胞計數器，並驗證 HemoScreen 在這些環境中的性能特徵。 因此，證明技術先進產品有效性的研究將推動市場持續創新並促進市場增長。 因此，由於上述因素，預計血液學市場在預測期內將出現顯著增長。 然而，新興國家的高設備成本和低採納血液分析儀預計將阻礙未來幾年的市場增長。

血液學市場趨勢

預計血細胞計數領域在預測期內將經歷顯著增長

血細胞計數器是一種用於根據血液樣本進行測試的設備。 它用於全血細胞計數測試，包括紅細胞、白細胞、血小板和血紅蛋白計數，以及用於疾病診斷的血細胞表徵。 血液相關疾病負擔的增加正在推動對血液學檢測的需求，而開發具有先進功能的血液分析儀的技術進步正在推動所研究細分市場的增長。是推動血液學檢測的主要因素

例如，2020 年 5 月，丹納赫公司的子公司貝克曼庫爾特在美國推出了 DxH 690T 血液學分析儀，使中型實驗室能夠簡化工作流程並最大限度地延長正常運行時間。 此外，2022 年 7 月，Horiba 宣布了 Yumizen H500 和 H550 血液學產品系列的新成員，這是一款緊湊型台式血液學分析儀，具有改進的性能、新功能和更多優勢。 這些產品提供快速和全面的血液學報告，吞吐量為 60 次測試/小時，40 支管的自主性，連續加載，緊急手動模式和樣本執行，具有多分析模式和採樣專為

此外，越來越多的研究和開發活動證明了血細胞計數器的有效性，預計會對市場增長產生積極影響。 例如，根據 2021 年 2 月發表的一項題為“為癌症醫院的血細胞計數器建立改進的審查標準”的研究，自動血細胞計數器廣泛用於醫學實驗室。僅此而已。 預計此類醫院條件將推動細胞表面標記檢測市場的研究血細胞計數器部分。

此外，主要公司的收購、聯盟和聯合研究等戰略聯盟正在推動該細分市場的增長。 例如，2020 年 9 月，Scient 與 Agape 建立了製造合作夥伴關係，在其位於印度的 ISO 13485 認證的最先進製造工廠製造 Mispa Count X 的某些關鍵部件。 Mispa Count X 是由 Agappe 設計和開發的三部分血細胞計數器。

因此，由於上述因素，預計所研究的細分市場將在研究期間對市場的增長做出積極貢獻。

北美地區擁有最大的市場份額，預計在預測期內將繼續保持同樣的趨勢

由於血液病發病率增加、技術進步和該地區產品發布增加等因素，預計未來幾年北美地區的美國血液學市場將出現顯著增長。. 根據美國國家癌症研究所 2021 年 10 月的更新，急性髓性白血病是成人中最常見的急性白血病類型。 根據白血病和淋巴瘤協會 2021 年的統計數據，美國估計還有 397,501 人患有或正在緩解白血病。 預計白血病等血液病負擔的增加將激增對血液學儀器和試劑的需求，從而推動該地區的市場增長。 根據 2021 年 7 月發表的一項研究，鐵攝入量減少與美國人口中缺鐵性貧血和相關死亡率的上升相平行，美國貧血的估計患病率在 10.5% 到 106% 之間，具體取決於年齡和性別。% . 因此，它在該國的高流行率需要進行大量血液檢測，從而推動市場。

此外，2020 年 10 月，CellaVision AB 推出了 CellaVision DC-1，這是一種自動細胞定位設備，旨在用於臨床實驗室的體外診斷，具有白細胞計數和紅細胞形態學差異。CellaVision DC-1 PPA已獲得美國食品和藥物管理局 510(k) 上市前許可，用於表徵和血小板估計。 此外，2020 年 11 月，Sysmex America 宣布將為美國和加拿大的小容量血液實驗室銷售 FDA 批准的 ClearVision DC-1。 此外，2022 年 1 月，Sight Diagnostics 獲得了加拿大衛生部的批准，可以為現場護理設置提供 Sight OLO 分析儀。 通過其分銷合作夥伴 Inter Medico，Sight 計劃通過向加拿大各地的急診室、醫院和其他分散環境提供五部分血液檢測來引領市場。

因此，由於上述因素，預計北美地區的市場在預測期內將出現顯著增長。

血液學檢測市場競爭分析

血液學市場分散且競爭激烈。 主要行業參與者包括 Abbott Laboratories、Bio-Rad Laboratories Inc.、Danaher Corporation、Siemens Healthineers 和 F. Hoffmann-La Roche Ltd。 每家公司都採取了某些戰略舉措，例如合併、新產品發布、收購、合作夥伴關係以及對研發活動的投資，這有助於加強其在全球市場的地位。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 血液病和其他疾病的發病率增加
    • 血液學的快速技術進步
    • 高通量血細胞計數器的出現
  • 市場製約因素
    • 設備成本高
    • 血細胞計數器在新興國家的滲透率低
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：單位：百萬美元）

  • 按產品分類
    • 血細胞計數器
    • 流式細胞儀
    • 凝血分析儀
    • 載玻片染色機
    • 離心機
    • 血紅蛋白計
    • 其他產品
  • 按試劑
    • 凝血試劑
    • 流式細胞術試劑
    • 免疫血液學試劑
    • 其他試劑
  • 通過申請
    • 藥物測試
    • 自身免疫性疾病
    • 癌症
    • 糖尿病
    • 感染
    • 其他應用
  • 最終用戶
    • 醫院
    • 實驗室
    • 患者自我診斷
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • Diatron MI PLC（Stratec Biomedical Systems）
    • F.Hoffmann-La Roche AG
    • Novo Nordisk AS
    • Fluidigm Corporation
    • Drew Scientific Group
    • PerkinElmer Inc.
    • Thermo Fisher Scientific Inc.
    • Ortho Clinical Diagnostics
    • Siemens Healthineers
    • Sysmex Corporation
    • Shenzhen Mindray Bio-Medical Electronics Co. Ltd

第7章 市場機會與今後動向

簡介目錄
Product Code: 53511

The hematology market is expected to record a CAGR of 5.2% over the forecast period (2022-2027).

The COVID-19 outbreak is expected to have a significant impact on the hematology market as there is an increasing focus on hematology parameters for the assessment of COVID-19 around the world, and many hospitals have started using instruments such as hematology analyzers to test and monitor COVID-19 patients. According to the research article published in the International Journal of Laboratory Hematology, 2020, a clinical hematology laboratory has a critical role in providing several useful prognostic markers such as lymphopenia, neutrophilia, leukocytosis, and thrombocytopenia, which are common findings in patients infected with SARS-CoV-2 virus. According to the report published in the American Society of Hematology 2021, Patients with COVID-19 and sickle cell disease (SCD) remained at a higher risk of hospitalization, pneumonia development, and pain when compared to Black people without SCD. As the people with SCD were at higher risk of developing other infections, it was important to monitor their health which has considerably impacted the market. Thus, the growing importance of hematological testing in COVID-19 infected patients is expected to surge the demand for hematology products and reagents across various end users, thereby significantly impacting the studied market's growth during the pandemic era.

The growth of the hematology market is attributed to the increasing incidences of blood disorders and other diseases, rapid technological advances in hematology, and the emergence of high throughput hematology analyzers. The increasing prevalence of chronic blood disorders is one of the major factors driving the market, as it is expected to drive the demand for hematology analyzers. Coagulation analyzers can accurately detect the clotting endpoint in various blood disorders, such as hemophilia. People can be affected by various types of blood conditions and blood cancers. Common chronic blood disorders include anemia, bleeding disorders such as hemophilia and blood clots, and blood cancers such as leukemia, lymphoma, and myeloma. As per the May 2022 update by the Center for Disease Control and Prevention, sickle cell disease (SCD) affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African American births. Early diagnosis and treatment are the best ways to protect the life of a patient with blood cell disorder.

Additionally, the technological advancements and product launches by key players have been driving the market growth. For instance, in June 2022, Thermo Fisher Scientific Inc. introduced the new EliA RNA Pol III and EliA Rib-P blood tests for aiding in the diagnosis of Systemic Sclerosis and Systemic Lupus Erythematosus (SLE), thus further expanding its comprehensive menu of automated connective tissue disease tests. According to an article "RURAL Study to Use HemoScreen POC Hematology Analyzer" published in February 2021, the Risk Underlying Rural Areas Longitudinal Study (RURAL) was conducted to understand the health concerns facing people in rural communities who don't have the same healthcare access as urban parts. This study plans to deploy technology advanced HemoScreen hematology analyzers in the Mobile Examination Unit lab to test the performance characteristics of the HemoScreen in those setting. Thus, the research proving the efficacy of technologically advanced product will boost the ongoing innovation in the market, thus fueling the market growth. Thus, owing to the abovementioned factors, the hematology market is expected to witness significant growth over the forecast period. However, the high cost of the instruments and the low adoption of hematology analyzers in the emerging economies are anticipated to hamper the market growth in the coming years.

Hematology Market Trends

The Hematology Analyzers Segment is Expected to Register Significant Growth Over the Forecast Period

Hematology analyzers are instruments used to run tests based on blood samples. They are used to perform tests such as complete blood count, including red blood cell, white blood cell, platelet, and hemoglobin count, along with characterizing the blood cells to diagnose a disease condition. The growing burden of blood-related disorders, which drives the demand for hematology tests, and advancements in technology for the development of hematology analyzers with advanced features are the major drivers for the growth of the studied segment.

For instance, in May 2020, Beckman Coulter, a subsidiary of Danaher Corporation, launched its DxH 690T hematology analyzer in the United States, which enables mid-volume laboratories to streamline workflow and maximize uptime. Additionally, in July 2022, HORIBA Medical launched new products in its Yumizen H500 & H550 hematology product family, the compact benchtop hematology analyzers with enhanced performance, new features, and increased benefits. These products have been designed to deliver a rapid and comprehensive hematology report with a throughput of 60 tests/hour, 40 tubes autonomy with continuous loading, urgent manual mode; and for running samples through multi-analysis modes and sampling.

Moreover, rising research and development activities proving the efficacies of hematology analyzers are expected to positively contribute to the market growth. For instance, according to a study titled 'Establishment of improved review criteria for hematology analyzers in cancer hospitals' published in February 2021, automated hematologic analyzers are widely used in medical laboratories. This condition in the hospitals will boost the studied hematology analyzers segment of the cell surface markers detection market.

Also, strategic alliances such as acquisitions, partnerships, and collaborations by key players are driving the segment growth. For instance, in September 2020, Cyient entered a manufacturing partnership with Agappe to manufacture certain key components of Mispa Count X at its ISO 13485-certified, state-of-the-art manufacturing facilities in India. The Mispa Count X is an indigenously designed and developed three-part hematology analyzer by Agappe.

Thus, due to the above-mentioned factors, the studied segment is expected to contribute positively to the market growth during the study period.

The North American Region Holds the Largest Market Share, and it is Expected to Follow the Same Trend over the Forecast Period

The United States within North America is expected to witness significant growth in the hematology market in the coming years due to factors such as the increasing incidence of blood disorders, technological advancements, and increasing product launches in the region. As per an October 2021 update by the National Cancer Institute, acute myeloid leukemia is the most common type of acute leukemia in adults. In addition, as per the 2021 statistics by the Leukemia & Lymphoma Society, an estimated 397,501 people are living with or in remission from leukemia in the United States. The growing burden of blood disorders such as leukemia is expected to surge the demand for hematology instruments and reagents, thus driving the market growth in the region. According to the study "Decreased Iron Intake Parallels Rising Iron Deficiency Anemia and Related Mortality Rates in the United States Population" published in July 2021, the prevalence of estimated anemia in the United States ranged from 10.5% to 106% depending on the age and sex. Thus, the high prevalence of the disease in the country demands a high number of blood tests, thus driving the market.

Additionally, in October 2020, CellaVision AB received the United States Food and Drug Administration's 510(k) premarket approval for its CellaVision DC-1, which is an automated cell-locating device intended to be used in in vitro diagnostics in clinical laboratories, and CellaVision DC-1 PPA, which is intended for the differential count of white blood cells, characterization of red blood cell morphology, and platelet estimation. Further, in November 2020, Sysmex America announced that it would distribute the FDA-cleared ClearVision DC-1 for low-volume hematology laboratories in the United States and Canada. Additionally, in January 2022, Sight Diagnostics received Health Canada approval to provide Sight OLO analyzers for point-of-care settings. Through its distribution partner Inter Medico, Sight will bring the 5-part differential blood testing to emergency departments, hospitals, and other decentralized settings across Canada, thereby driving the market.

Thus, owing to the abovementioned factors, the market is expected to witness significant growth in the forecast period in the North American region.

Hematology Market Competitor Analysis

The hematology market is fragmented and moderately competitive. Some key industry players include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens Healthineers, F. Hoffmann-La Roche Ltd etc. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, partnerships, and investments in research and development activities, which help them strengthen their market positions globally.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidences of Blood Disorders and Other Diseases
    • 4.2.2 Rapid Technological Advances in Hematology
    • 4.2.3 Emergence of High Throughput Hematology Analyzers
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Instruments
    • 4.3.2 Low Adoption of Hematology Analyzers in Emerging Economies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product
    • 5.1.1 Hematology Analyzers
    • 5.1.2 Flow Cytometers
    • 5.1.3 Coagulation Analyzers
    • 5.1.4 Slide Stainers
    • 5.1.5 Centrifuges
    • 5.1.6 Hemoglobinometers
    • 5.1.7 Other Products
  • 5.2 By Reagent
    • 5.2.1 Coagulation Reagents
    • 5.2.2 Flow Cytometery Reagents
    • 5.2.3 Immuno-hematology Reagents
    • 5.2.4 Other Reagents
  • 5.3 By Application
    • 5.3.1 Drug Testing
    • 5.3.2 Auto-immune Diseases
    • 5.3.3 Cancer
    • 5.3.4 Diabetes Mellitus
    • 5.3.5 Infectious Diseases
    • 5.3.6 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Clinical Testing Institutes
    • 5.4.3 Patient Self-testing
    • 5.4.4 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 Bio-Rad Laboratories Inc.
    • 6.1.4 Danaher Corporation
    • 6.1.5 Diatron MI PLC (Stratec Biomedical Systems)
    • 6.1.6 F.Hoffmann-La Roche AG
    • 6.1.7 Novo Nordisk AS
    • 6.1.8 Fluidigm Corporation
    • 6.1.9 Drew Scientific Group
    • 6.1.10 PerkinElmer Inc.
    • 6.1.11 Thermo Fisher Scientific Inc.
    • 6.1.12 Ortho Clinical Diagnostics
    • 6.1.13 Siemens Healthineers
    • 6.1.14 Sysmex Corporation
    • 6.1.15 Shenzhen Mindray Bio-Medical Electronics Co. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS